Jinfiniti supplies diagnostic services to physicians and hospitals through our cell culturing technology. These services include early detection through screening Pap tests and suspicious tissues such as colon polyps. These are preventive and personalized services that optimize cancer care by diagnosing cancer subtypes and identifying actionable mutations early.How we detect cancer
Jinfiniti provides biomedical research and services to researchers who wish to culture, amplify, test, and store their tumor samples to create a perpetual supply of living cancer cells for future tests.How we store living cancers
Jinfiniti's laboratory research services includes BEATtumor℠, a chemosensitivity test that predicts how well patients respond to your drugs. We use this predictive medicine test to identify key patient populations for your clinical trials or identifying new patient populations for repurposing your drugs.How we help with clinical trials
Control for genetic and environmental variations between individuals by testing your clinical trial drugs on amplified primary cancer cells from the same tumor. This allows for direct comparisons between drugs for each patient sample, giving you efficient and powerful results.
Jinfiniti lowers the risk of clinical trial failures by identifying patient populations that may benefit from your drugs. Supply us with your chemotherapy drugs and we will use them in our chemosensitivity test. Patients whose tumor samples respond well against your drugs may be good candidates for clinical trials.
Finding patients who respond to your drugs may allow us to discover unknown patient populations that may benefit. These patients may benefit from a new clinical trial to rescue or repurpose your drugs.
Jinfiniti's tumor amplification process can detect cancer cells from a sample containing as few as 10 cancer cells, making it a perfect early detection companion test for regular screenings such as colonoscopies, endoscopies, and pap smears. This high sensitivity is also used to detect minimum residual disease and cancer recurrence after treatment.
Women with undiagnosed ovarian and uterine cancer may benefit from using SpotTumor℠ as a companion test for their routine Pap test.
If you have any questions or would like to discuss a partnership, please fill out the form and we will contact you.
You may also email us at email@example.com